AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down – Time to Sell?

AbCellera Biologics Inc. (NASDAQ:ABCL) gapped down prior to trading on Wednesday . The stock had previously closed at $9.76, but opened at $9.22. AbCellera Biologics shares last traded at $9.6910, with a volume of 2,981,112 shares trading hands.

Key AbCellera Biologics News

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: Strong Phase 2 menopause data: Positive results for ABCL635 improved the outlook for AbCellera’s clinical pipeline and prompted discussion that the stock’s bullish case may have strengthened. The data could increase the program’s partnering and commercial potential. AbCellera Biologics Is Up 60.3% After Strong Phase 2 Menopause Data
• Positive Sentiment: Jazz Pharmaceuticals collaboration supports valuation: The company’s Jazz deal, together with the clinical update, led to a reported lift in fair-value estimates and reinforced expectations for future milestone or partnership opportunities. AbCellera Stock Sees Fair Value Lift After Clinical Data and Jazz Deal
• Positive Sentiment: Analyst support and options activity: A Truist Financial analyst reportedly expects ABCL’s stock to rise, while unusually high call-option purchases indicate increased speculative bullish interest. These signals may be adding momentum, although they do not guarantee longer-term performance. Truist Analyst Expects AbCellera Stock to Rise
• Neutral Sentiment: Oversubscribed financing improves liquidity: AbCellera priced an oversubscribed public offering expected to generate approximately $200 million in gross proceeds, consisting of 17,435,897 common shares and pre-funded warrants for up to 3,076,926 additional shares at $9.75 per share. The funding gives the company more capital to advance its programs and operations. AbCellera Announces Pricing of Oversubscribed $200 Million Offering
• Negative Sentiment: Share dilution is a near-term risk: Issuing millions of new shares and warrants increases the company’s share count and may pressure the stock, particularly because the offering price is below recent trading levels. Investors must weigh the stronger balance sheet against reduced ownership on a per-share basis. AbCellera Prices Oversubscribed $200 Million Offering at $9.75

Wall Street Analyst Weigh In

ABCL has been the subject of several recent research reports. Cantor Fitzgerald increased their target price on shares of AbCellera Biologics from $11.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Benchmark raised AbCellera Biologics from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Tuesday, July 7th. Stifel Nicolaus increased their price objective on AbCellera Biologics from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Truist Financial lifted their target price on AbCellera Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Wall Street Zen lowered AbCellera Biologics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $12.83.

AbCellera Biologics Trading Up 6.0%

The company has a market cap of $3.36 billion, a price-to-earnings ratio of -20.31 and a beta of 1.20. The company’s 50 day moving average price is $6.54 and its 200 day moving average price is $4.86.

AbCellera Biologics (NASDAQ:ABCL) last issued its earnings results on Wednesday, August 5th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.02). AbCellera Biologics had a negative net margin of 248.83% and a negative return on equity of 17.49%. The firm had revenue of $4.05 million during the quarter, compared to analysts’ expectations of $7.85 million. Sell-side analysts predict that AbCellera Biologics Inc. will post -0.68 earnings per share for the current year.

Institutional Investors Weigh In On AbCellera Biologics

A number of institutional investors have recently added to or reduced their stakes in ABCL. AssuredPartners Investment Advisors LLC purchased a new position in shares of AbCellera Biologics during the 4th quarter worth approximately $34,000. Voleon Capital Management LP acquired a new stake in shares of AbCellera Biologics in the 3rd quarter valued at approximately $56,000. Engineers Gate Manager LP purchased a new stake in shares of AbCellera Biologics in the fourth quarter valued at approximately $38,000. Allworth Financial LP boosted its stake in shares of AbCellera Biologics by 857.0% in the fourth quarter. Allworth Financial LP now owns 11,274 shares of the company’s stock valued at $39,000 after buying an additional 10,096 shares in the last quarter. Finally, Janney Montgomery Scott LLC acquired a new position in AbCellera Biologics during the first quarter worth $46,000. Hedge funds and other institutional investors own 61.42% of the company’s stock.

AbCellera Biologics Company Profile

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.